Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Osteopore Ltd. ( (AU:OSX) ) has issued an announcement.
Osteopore Limited has entered an exclusive commercialisation agreement with Majeton to distribute its dental, orthodontic and maxillofacial regenerative implants across China, Hong Kong and Macau, marking a strategic move to penetrate the Greater China market. The deal, effective from 15 January 2026, includes staged payments tied to regulatory and sales milestones, such as upfront dossier fees, payments on regulatory approvals in Macau and China, and volume-based bonuses for units sold in the Greater Bay Area and mainland China, signalling a structured pathway to revenue growth and broader regional adoption of Osteopore’s technology.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
More about Osteopore Ltd.
Osteopore Limited is an Australian-Singaporean medical technology company focused on regenerative medicine, specialising in 3D-printed biomimetic and bioresorbable implants designed to enable natural bone healing in dental, orthodontic, maxillofacial and other therapeutic areas. Its patented, proprietary 3D-printing technology produces micro-structured polymer scaffolds that gradually dissolve to support healthy bone regeneration while reducing post-surgery complications associated with permanent implants.
Average Trading Volume: 1,483,558
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$2.26M
See more data about OSX stock on TipRanks’ Stock Analysis page.